Charles River Laboratories (CRL) Tops Q2 EPS by 32c, Lifts Guidance

Charles River Laboratories (NYSE: CRL) reported Q2 EPS of $1.58, $0.32 better than the analyst estimate of $1.26. Revenue for the quarter came in at $682.6 million versus the consensus estimate of $641.63 million.

GUIDANCE:

Charles River Laboratories sees FY2020 EPS of $7.05-$7.35, versus the consensus of $6.91.

• Revenue growth, reported 7.5% – 9.0%

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Citi upgrades Fifth Third Bancorp to Buy with $62 price target
• Turning Point Brands (TPB) PT Lowered to $90 at Oppenheimer